Table 1 Summary of patients’ characteristics.

From: Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study

Age (years)

Mean ± SD (N)

54.04 ± 10.77 (82)

Median (25th–75th)

56.5 (48–62)

Min–Max

24–78

Gender

Female

31 (37.8%)

Male

51 (62.2%)

ECOG

0

48 (58.5%)

1

29 (35.4%)

2

5 (6.1%)

Mobilization Regimen

DHAOX

3 (3.7%)

DHAP

29 (35.4%)

GIFOX

1 (1.2%)

IEV

16 (19.5%)

IGEV

1 (1.2%)

IVAC

1 (1.2%)

R-DHAOX

5 (6.1%)

R-DHAP

20 (24.4%)

R-EPOCH

1 (1.2%)

R-ICE

2 (2.4%)

R-IEV

2 (2.4%)

R-MTX ARAC HD

1 (1.2%)

Duration of mobilization regimen

2 days

58 (70.7%)

3 days

21 (25.6%)

4 days

1 (1.2%)

5 days

2 (2.4%)

Conditioning regimen

BEAM

23 (28%)

FEAM

46 (56.1%)

Melphalan/Mitoxatrone

1 (1.2%)

None

12 (14.6%)

  1. The table reports age, gender, the ECOG performance status, and the chemotherapy regimen administered of all 82 patients enrolled in the study.
Back to article page